Although we cannot rule out the possibility of off-target effects associated with tubastatin, our findings suggest that simultaneous targeting of HDAC6 and BET proteins (e.g., using tubastatin and apabetalone), may overcome complement-mediated resistance mechanisms within the GBM microenvironment. This evidence concerns the gene DNER and glioblastoma.